Antibody-dependent enhancement of yellow fever virus neurovirulence, as measured by a reduction in the average survival time of groups of mice, was demonstrated with wild-type or vaccine strains of yellow fever virus and with Japanese encephalitis virus using intraperitoneally administered monoclonal antibodies specific for the viral E glycoprotein of yellow fever virus. Enhancement of virulence could be induced by neutralizing, non-neutralizing or protective antibodies if the virus was allowed to establish a productive infection in the mouse brain before the antibody was administered. The implications of antibody-dependent enhancement in flaviviruses are discussed.
* Groups of 30 mice were inoculated intracerebrally with YF FNV virus (100 LDso/mouse). Three days later they were inoculated intraperitoneally with 0.1 ml of MAb as ascitic fluid. Monoclonal antibody 294 was prepared against hepatitis B virus surface antigen. molecular specificities of these were as described by Gould et al. (1985) . Random bred female Swiss mice, strain TO, were obtained from Tuck and Sons. They were used when aged 3 to 4 weeks unless stated otherwise. All experiments were performed three times using 10 mice per group per experiment.
Monoclonal antibodies specific either for the E or the non-structural NS 1 glycoprotein of YF virus and serum RH1 were each used to look for virulence enhancement with the FNV strain of YF virus. Groups of 10 mice were inoculated intracerebrally with an estimated 100 LDs0/mouse of FNV virus. Three days post-infection, the mice were given 0.1 ml of the appropriate MAb or RH 1 intraperitoneally. At this time the mice were healthy, but we know from previous analyses (Gould et al., 1987) that infectious virus was present in the brain. The average survival time was estimated and compared with that for control mice inoculated with a MAb specific for hepatitis B virus surface antigen (MAb 294). Significant enhancement of neurovirulence occurred (P < 0.001) with all E-specific MAbs except MAb 810 (Table 1) . This antibody has an IgM isotype. Enhancement was also seen with RH1 which reacts with viral E protein, but enhancement was not seen with MAb 863 or 979 both of which are specific for YF virus NSI antigen (Gould et al., 1985) .
Wild-type or vaccine strains of YF virus with differing levels of neurovirulence for mice (see Barrett & Gould, 1986) were given intracerebrally (100 LD5o/mouse) to groups of 10 mice. Five days post-infection the mice were given 0.1 ml of MAb 427 or control MAb 294 intraperitoneally. At this stage the mice appeared healthy.
With the exception of YF RMP virus, a substrain of the 17D vaccine strain, significant enhancement of virus neurovirulence was observed, with all strains of YF virus (Table 2) . YF RMP virus has previously been shown to have extremely low virulence for mice, and under the experimental conditions employed little if any infectious virus would be expected to be found in the brains (Gould et al., 1986) . It must be emphasized that many of these E-specific MAbs do protect mice against challenge with YF virus if the MAbs are administered intraperitoneally at the time of virus challenge (Gould et al., 1986) .
A limited series of experiments was then performed in preliminary attempts to enhance the neurovirulence of flaviviruses other than YF virus. Initially, MAbs against YF virus that were known to react with the E protein of JE, West Nile, louping ill (LI) (MAbs 427, 813 and 843), tick borne encephalitis (TBE), Murray Valley encephalitis (MVE) viruses and each of the four dengue serotypes (MAb 813) were given intraperitoneally to groups of 10 mice (0.1 ml/mouse) followed immediately by 100 LDs0/mouse of appropriate virus (as indicated above), 
YF virus strains when
* Groups of 30 mice were inoculated intracerebrally with the YF viruses indicated (100 LDso/mouse). Three days later they were given 0.1 ml of either MAb 427 or control MAb 294 intraperitoneaUy. administered intracerebrally. There was no significant enhancement of virus neurovirulence. In further experiments antibodies were given intraperitoneally to virus-infected mice approximately 3 days before death would normally be expected (Table 1 ). Significant (P< 0.001) enhancement of JE virus neurovirulence was seen only with MAb 427. The neurovirulence of the other flaviviruses shown in Table 3 was not affected. Previously, we demonstrated that antibody-dependent enhancement of FNV virus neurovirulence occurred if the virus could reach a high titre in the mouse brain in the presence of antibody. We also found that enhancement was most readily achieved with two MAbs that showed poor neutralizing ability against the virus (Gould et al., 1987) . In the present experiments we have shown that the relative neurovirulence of a range of YF viruses was enhanced by a variety of MAbs. Both neutralizing and non-neutralizing antibodies were able to induce enhancement. Nevertheless, antibodies normally capable of protecting mice from virus challenge enhanced neurovirulence only if they were given at a time after infection when the viruses had established infection in the mouse brain. Failure to enhance the neurovirulence of YF RMP virus was probably due to lack of sufficient virus in the infected brains (Gould et al., 1986) . Our data are consistent with the previous concept (Gould et al., 1987) that enhancement, as measured by a decrease in the average survival time, arises directly as the result of interaction in the brain between virus and antibody without an increase in viral titres. In a previous report we were unable to enhance JE (Nakayama strain) virus neurovirulence (Barrett & Gould, 1986) . This was possibly because the antibody was administered at the time of virus challenge.
Thus far, we have successfully enhanced the virulence of two flaviviruses, i.e. YF and JE viruses. The exact reasons for this apparent specificity are not entirely clear; however, it seems reasonable to assume that the choice of antibodies and the exact experimental conditions are critical for enhancement. A similar suggestion was made by Webb et al. (1968) who reported enhanced neurovirulence of Langat virus for mice using passively administered antibody. In their case, enhancement was seen only if antibody was given 2 or 3 days post-infection. We have confirmed this observation (unpublished results).
With flaviviruses, we have not observed enhancement of virulence by antibodies other than those specific for the viral E protein. In a recent report by Henchal et al. (1988) it was stated that dengue virus morbidity for mice was increased in the presence of dengue anti-NS1 antibodies.
Further investigations seem justified to determine the extent of immune enhancement in the flavivirus genus.
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